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Abstract
Preclinical studies suggest that diets rich in omega-3 polyunsaturated fatty acids (n-3 PUFAs) may be beneficial
for prevention of pancreatic cancer. Nutritional intervention studies are often complex, and there is no clear evi-
dence, without potential confounding factors, on whether conversion of n-6 PUFAs to n-3 PUFAs in pancreatic
tissues would provide protection. Experiments were designed using n-3 fatty acid desaturase (Fat-1) transgenic
mice, which can convert n-6 PUFA to n-3 FAs endogenously, to determine the impact of n-3 PUFAs on pancreatic
intraepithelial neoplasms (PanINs) and their progression to pancreatic ductal adenocarcinoma (PDAC). Six-week-
old female p48Cre/+–LSL-KrasG12D/+ and compound Fat-1–p48Cre/+–LSL-KrasG12D/+ mice were fed (AIN-76A)
diets containing 10% safflower oil for 35 weeks. Pancreata were evaluated histopathologically for PanINs and
PDAC. Results showed a dramatic reduction in incidence of PDAC (84%; P < .02) in Fat-1–p48Cre/+–LSL-
KrasG12D/+ mice compared to p48Cre/+–LSL-KrasG12D/+ mice. Importantly, significant reductions of pancreatic
ducts with carcinoma (90%; P < .0001) and PanIN 3 (∼50%; P < .001) lesions were observed in the compound
transgenic mice. The levels of n-3 PUFA were much higher (>85%; P < .05–0.01) in pancreas of compound trans-
genic mice than in those of p48Cre/+–LSL-KrasG12D/+ mice. Molecular analysis of the pancreas showed a significant
down-regulation of proliferating cell nuclear antigen, cyclooxygenase-2, 5-lipoxygenase (5-LOX), 5-LOX–activating pro-
tein, Bcl-2, and cyclin D1 expression levels in Fat-1–p48Cre/+–LSL-KrasG12D/+ mice compared to p48Cre/+–LSL-
KrasG12D/+ mice. These data highlight the promise of dietary n-3 FAs for chemoprevention of pancreatic cancer in
high-risk individuals.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive can-
cer with a dismal 5-year survival rate (<5%) and usually is diagnosed
in an advanced stage with no curative therapies. Developing novel
strategies to prevent or delay the progression of PDAC is of utmost
importance. In 2012, more than 43,920 Americans will be diagnosed
with pancreatic cancer and there will be about 37,390 deaths from
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this disease [1]. The high mortality rate is due, in part, to difficulties in
establishing an early and accurate diagnosis and, in part, to the lack of
effective prevention strategies [2,3]. Current therapies for managing
pancreatic cancer lack efficacy, and an urgent need remains for the
development of novel strategies for prevention and treatment. Activat-
ing K-ras mutations, mostly at codon 12, occur in more than 95% of
the patients with PDAC [2–4]. It is well known that the initiation of
the disease begins with genetic alteration in the K-ras gene in the nor-
mal pancreatic ductal cell followed by inactivation of tumor suppressor
genes (CDNK2A and p53) and activation of growth signaling pathways
(epidermal growth factor receptor and insulin-like growth factor) [5,6].
Mice harboring a conditional K-ras mutant allele (LSL-KrasG12D/+) in
combination with a pancreas-specific Cre recombinase transgene
(p48Cre/+) develop a full range of premalignant pancreatic intraepithelial
neoplasm (PanIN) lesions in the pancreas before succumbing to inva-
sive PDAC and other tumors at late ages [7,8].
From a dietary perspective, published data indicate that bioactive
lipids containing omega-3 polyunsaturated fatty acids (n-3 PUFAs)
modulate a wide array of chronic diseases, including tumor develop-
ment and its progression [9,10]. PUFAs are constituents of membrane
phospholipids that serve as precursors for signaling eicosanoids includ-
ing prostaglandins (PGs), thromboxanes, and leukotrienes (LTs) [11].
The principal PUFA, arachidonic acid (AA; C20:4n-6), is the source of
PGE2 and LTB4, which have been shown to promote tumor growth
and metastasis, whereas n-3 PUFAs, eicosapentaenoic acid (EPA;
C20:5n-3) and docosahexaenoic acid (DHA)–derived eicosanoids,
show tumor-suppressive effects [12–14]. Evidence suggests that the
n-6:n-3 FA ratio, rather than the absolute levels of these two classes of
PUFAs, is the primary factor that influences the tumorigenesis [15–19].
It has been estimated that theWestern diet is deficient in n-3 PUFAs
with a ratio of ∼15:1 n-6 to n-3 PUFAs and this high n-6/n-3 ratio is a
risk factor for many cancers [19]. The health benefits of n-3 PUFAs are
thought to stem mainly from the EPA and DHA metabolites, type 3
series eicosanoids (e.g., PGE3) compared to AA metabolites of pro-
inflammatory type 2 series eicosanoids (e.g., PGE2) [20,21]. Most of
the preclinical studies using mouse models demonstrate that dietary
intake of n-3 PUFAs (e.g., in the form of diets with a low n-6/n-3
PUFA ratio) reduces the incidence and growth of various cancers,
including pancreatic cancer [22–25]. In chemically induced pancreatic
carcinogenesis models, fish oils were capable of reducing the incidence
of pancreatic cancers and hepatic metastases [25,26].
An important nutritional question as to whether the ratio of n-6:
n-3 FAs plays a role in pancreatic tumorigenesis remains to be clarified
in well-characterized experimental models of pancreatic cancer. Because
95% of human pancreatic cancers are associated with K-ras mutations,
it is important to understand whether K-rasG12D–activated pancreatic
cancers would be inhibited by increased n-3 FA without any experi-
mental confounding factors. The recently engineered n-3 fatty acid
desaturase (Fat-1) mice, which can convert n-6 to n-3 FAs and have
a balanced ratio of n-6 to n-3 FAs in their tissues, allow carefully con-
trolled studies to be performed in the absence of potential confounding
dietary factors. The Fat-1 gene encodes an n-3 FA desaturase that
catalyzes conversion of n-6 to n-3 FAs. This allows production of
two different FA profiles (high vs low n-6/n-3 ratios) in the animals
without or with the Fat-1 gene by using just a single diet, thus elimi-
nating the potential diet variations. Hence, the Fat-1 transgenic mouse
is a valuable in vivo system for elucidating the role of n-3 FAs and the
n-6/n-3 ratio in carcinogenesis. The p48Cre/+–LSL-KrasG12D/+ pan-
creatic cancer transgenic mice were bred with Fat-1 mice to generate
compound Fat-1–p48Cre/+–LSL-KrasG12D/+ transgenic mice. In this
study, we fed compound transgenic mice a high n-6–containing diet
with 10% safflower oil to test whether endogenous n-3 PUFAs affect
the incidence of PanINs and their progression to PDAC. We analyzed
amounts of n-3 PUFAs, n-6/n-3 ratio, and various signaling molecules
involved in the PDAC development.
Materials and Methods
Animals, Diets, and Care
All animal experiments were done in accordance with the institu-
tional guidelines of the American Council of Animal Care. All the
mice are in the C57BL/6 background. Required quantities of acti-
vated p48Cre/+–KrasG12D/+ [3,27,28], Fat-1, and Fat-1–Kras com-
pound mice were generated as described. Animals were housed in
ventilated cages under standardized conditions (21°C, 60% humid-
ity, 12-hour light/12-hour dark cycle, 20 air changes/hour) in the
University of Oklahoma Health Sciences Center Rodent Barrier
Facility. Semipurified modified AIN-76A diet ingredients and saf-
flower oil were purchased from Bioserv, Inc (Frenchtown, NJ).
The 10% safflower oil replacing corn oil in the modified AIN-76A
diet was blended using a Hobart Mixer. Mice were allowed ad libitum
access to the respective diets and to automated tap water purified by
reverse osmosis.
Breeding and Genotyping Analysis
Fat-1, LSL-KrasG12D/+, and p48Cre/+ mice were maintained in a
C57BL/6 heterozygous genetic background. Fat-1, LSL-KrasG12D/+,
and p48cre/+ mice were bred, and the offspring of female activated
p48Cre/+–LSL-KrasG12D/+, Fat-1–p48Cre/+–LSL-KrasG12D/+, Fat-1,
and C57BL/6 wild-type (WT) mice were generated at required quan-
tities. Briefly, genomic DNA was extracted from snap-frozen tail tissue
samples using the Miniprep Kit (Invitrogen, Carlsbad CA). Polymerase
chain reaction (PCR) was performed for K-ras and Cre genes using
the following conditions: denaturation at 95°C for 5 minutes, followed
by 35 cycles at 95°C for 1 minute, 60°C for 1 minute, and 72°C for
1 minute. Oligonucleotide primer sequences used were given as fol-
lows: K-ras, 5′-CCTTTACAAGCGCACGCAGAG-3′ (sense) and
5′-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3′ (anti-
sense) and Cre, 5′-ACCGTCAGTACGTGAGATATCTT-3′ (sense)
and 5′-ACCTGAAGATGTTCGCGATTATCT-3′ (antisense). PCR
was performed for Fat-1 gene using the following conditions: denatur-
ation at 94°C for 2 minutes, followed by 35 cycles at 94°C for 30 sec-
onds, 62°C for 20 seconds, and 72°C for 2 minutes. Oligonucleotide
primer sequences used for Fat-1 were given as follows: 5′-CTGCAC-
CACGCCTTCACCAACC-3′ (sense) and 5′-ACACAGCAGATTC-
CAGAGATT-3′ (antisense). PCR products were separated on a 2%
agarose gel. Successful recombination yields are 550-, 210-, 251-bp
products for Kras, Cre, and Fat-1 genes, respectively. The genotype of
each pup was confirmed by tail DNA extraction and PCR as described
elsewhere (Figure 1A) [3,27,28].
Bioassay Study
Genotyped female p48Cre/+–LSL-KrasG12D/+, Fat-1–p48Cre/+–LSL-
KrasG12D/+, Fat-1 transgenic, and WT mice were used in the bioassay
study. The experimental protocol is summarized in Figure 1B. Five-
week-old mice were selected and randomized so that average body
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weights in each group were equal (n = 12 p48Cre/+–LSL-KrasG12D/+
mice/group, n = 13 Fat-1–p48Cre/+–LSL-KrasG12D/+ mice/group, and
n = 12 C57BL/6 WT mice/group), and mice were fed AIN-76A diet
for 1 week. At 6 weeks of age, mice were fed experimental diets contain-
ing 10% safflower oil in the modified AIN-76A diet until termination
of the study. The used 10% safflower oil diet has an n-6/n-3 FA ratio of
274, with an FA composition having 72 molar percent 18:2n-6 and no
significant n-3 FAs. Previously, it was determined and subsequently
confirmed in further studies that feeding a 10% safflower oil diet to
Fat-1 mice effectively and efficiently alters the n-6/n-3 FA ratio of
lipid compositions of measured tissues. This diet has reproducibly pro-
vided the desired effect on the FA composition of tissues of interest.
Hence, we continued to use the 10% safflower oil diet for these Fat-1
studies [29–31]. Mice were checked routinely for signs of weight loss
or any signs of toxicity or abnormalities. Food intake and body weight
of each animal were measured once weekly for the first 6 weeks and
then once a month until termination (Figure 1C ). After 35 weeks
(∼9 months) on experimental diets, all mice were killed by CO2
asphyxiation and necropsied; pancreata were collected from all groups,
weighed, and snap frozen in liquid nitrogen for further analysis.
Figure 1. (A) Genotyping of offspring of p48Cre/+, LSL-KrasG12D/+, and Fat-1 mice by PCR (arrows on top indicate mice with activated
Kras and arrows on the bottom indicates mice with Fat-1 gene expression). (B) Experimental design for preventive efficacy evaluation
of endogenous n-3 FAs in female p48Cre/+–LSL-K-RasG12D/+ mice. At 6 weeks of age, groups (12 activated p48Cre/+.LSL-KrasG12D/+ or
13 Fat-1.p48Cre/+.LSL-KrasG12D/+/group and 12 WT/group) of mice were fed AIN-76A diets containing 10% safflower oil continuously for
35 weeks and each pancreas was evaluated histopathologically for various marker expressions as described in the text. (C) Effect of n-3
FAs on body weight (means ± SE, N = 13 or 12) at the termination of the experiment. No significant difference was observed between
Fat-1–p48Cre/+–LSL-KrasG12D/+ and p48Cre/+–LSL-KrasG12D/+mice or betweenWTand Fat-1mice.However non-Kras–activatedmice showed
an increased body weight gain compared with Kras-activated mice.
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Pancreata (head to tail) required for histopathologic and immuno-
histochemistry (IHC) evaluations, identification of PanIN lesions and
PDAC, and evaluation of various molecular markers were fixed in
10% neutral-buffered formalin.
Histologic Evaluation
Formalin-fixed, paraffin-embedded tissues were sectioned (4 μm)
and stained with hematoxylin and eosin (Figure 2, A–D). Sections of
each pancreas were evaluated histologically by a pathologist blinded
to the experimental groups as previously described [7,27,28]. PanIN
lesions and carcinoma were classified according to histopathologic
criteria as recommended elsewhere and our previous studies [7,27,28].
To quantify the progression of PanIN lesions, we determined the total
number of ductal lesions and their grade.
FA Analysis
FA profiles were determined for pancreas. Total lipids were extracted
following the method of Folch et al. [32] withmodifications [33]. To each
lipid extract, we added 15:0, 17:0, 23:0, and 30:3n-6 as internal stan-
dards. The lipid extracts were subjected to acid hydrolysis/methanolysis
to generate fatty acid methyl esters (FAMEs) [33]. FAMEs were sep-
arated from other lipids (primarily cholesterol) by TLC on Silica Gel
60 plates using a solvent system of 80:20 hexane/ether. FAMEs were
quantified using an Agilent Technologies 6890N gas chromatograph
with flame ionization detector [34].
Immunohistochemistry
The effects of n-3 PUFAs on expression of proliferating cell nuclear
antigen (PCNA), β-catenin, cyclooxygenase-2 (COX-2), Bcl-2, p21,
Figure 2. (A–D) Typical histologic appearance of the pancreas with/without PanIN/PDAC in Fat-1 (A), WT (B), Fat-1–p48Cre/+–LSL-
KrasG12D/+ (C), and p48Cre/+–LSL-KrasG12D/+ (D) mice. No evidence of PanINs or PDAC was seen in the pancreas of Fat-1 or WT mice.
(E) Pancreata of activated KrasG12D/+ (top) and WT (bottom) mice at 41 weeks of age. (F) Pancreata of p48Cre/+–LSL-KrasG12D/+ (top) or
Fat-1–p48Cre/+–LSL-KrasG12D/+ (bottom) mice at 41 weeks of age. As shown in E and F (top), the pancreata from p48Cre/+–LSL-KrasG12D/+
mice were increased in size, weight and thickness compared with those from normal (E, bottom) and Fat-1–p48Cre/+–LSL-KrasG12D/+
mice (F, bottom). Expression of Fat-1 with Kras (Fat-1–p48Cre/+–LSL-KrasG12D/+) significantly decreased the size of the pancreas com-
pared to Kras alone (p48Cre/+–LSL-KrasG12D/+). (G) Pancreas weights (means ± SE, N = 13 or 12) at the termination of the experiment.
The significant differences between Fat-1–p48Cre/+–LSL-KrasG12D/+ and p48Cre/+–LSL-KrasG12D/+ mice or WT and Fat-1 mice were ana-
lyzed by unpaired t test with Welch’s correction. (H) Effect of Fat-1 gene expression on the incidence (percentage of mice with carci-
nomas) of PDAC. (I) Percentage of carcinoma spread per pancreas. (J) Effect of Fat-1 expression on the PanIN multiplicity (means ± SE).
The data in H to J were analyzed by unpaired t test with Welch’s correction; values are considered statistically significant at P < .05.
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and 5-lipoxygenase (5-LOX) were evaluated by IHC as described
elsewhere. Briefly, paraffin sections were deparaffinized in xylene, rehy-
drated through graded ethanol solutions, and washed in phosphate-
buffered saline (PBS). Antigen retrieval was carried out by heating
sections in 0.01 M citrate buffer (pH 6) for 30 minutes in a boiling
water bath. Endogenous peroxidase activity was quenched by incuba-
tion in 3%H2O2 in PBS for 5 minutes. Nonspecific binding sites were
blocked using Protein Block for 20 minutes. Sections then were incu-
bated overnight at 4°C with 1:300 dilutions of monoclonal antibodies
against PCNA, β-catenin, COX-2, Bcl-2, p21, and pAKT (AbCam,
Cambridge, MA; Cell Signaling Technology, Danvers,MA; Santa Cruz
Biotechnology Santa Cruz, CA). After several washes with PBS, the
slides were incubated with appropriate secondary antibody for 2 hours
and then washed and incubated with avidin-biotin complex reagent
(Zymed Laboratories, Camarillo, CA). After rinsing with PBS, the
slides were incubated with the chromogen 3,3′-diaminobenzidine for
3 minutes, then rinsed and counterstained with hematoxylin. Non-
immune rabbit immunoglobulins were substituted for primary anti-
bodies as negative controls. Slides were observed under an Olympus
microscope 1X701, and digital computer images were recorded with
an Olympus DP70 camera.
Apoptosis Assay
Paraffin sections of 5-μm thickness mounted on slides were rehy-
drated and stained using the Fragment End Labeling (FragEL) DNA
Fragmentation Detection Kit with the terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) method following the
manufacturer’s instructions (Millipore, Billerica, MA). This kit allows
the recognition of apoptotic nuclei in paraffin-embedded tissue sec-
tions fixed on slide by FragEL of DNA. The terminal deoxynucleotidyl
transferase binds to exposed ends of DNA fragments generated in re-
sponse to apoptotic signals and catalyzes the template-dependent
addition of biotin-labeled and biotin-unlabeled deoxynucleotides.
Biotinylated nucleotides are detected using streptavidin-HRP conju-
gate. Diaminobenzidine reacts with the labeled sample to generate an
insoluble colored product at the site of DNA fragmentation. Counter-
staining with methyl green aids in themorphologic evaluation and char-
acterization of normal and apoptotic cells. Stained apoptotic epithelial
cells (a minimum of 10 microscopic fields per section) were counted
manually in a single-blind fashion.
Western Blot Analysis of Protein Expression
Pancreata harvested from mice were homogenized and lysed in ice-
cold lysis buffer [50 mMTris (pH 7.4), 150 mMNaCl, 1 mM EDTA,
1%NP-40, 50 mMNaF, 1 mM sodium orthovanadate, 1 mM PMSF,
1mMDTT, and 1× protease inhibitor cocktail (Sigma, St Louis,MO)].
After a brief vortexing, the lysates were separated by centrifugation at
12,000g for 15 minutes at 4°C, and protein concentrations were
measured with the Bio-Rad Protein Assay reagent (Bio-Rad, Hercules,
CA). An aliquot (50 μg protein/lane) of the total protein was separated
with 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes. After blocking with
5% milk powder, membranes were probed for expression of COX-2,
5-LOX, β-catenin, Bcl-2, caspase-3, PCNA, and β-actin in hybridizing
solution (1:500, in TBS–Tween 20 solution) using respective primary
antibodies (Cell Signaling Technology, AbCam, and Santa Cruz Bio-
technology) and then probed with their respective HRP-conjugated
secondary antibodies. Detection was performed using the SuperSignal
West Pico Chemiluminescence procedure (Pierce, Rockford, IL). The
bands were captured on Ewen Parker Blue sensitive X-ray films and
analyzed by densitometry.
Real-time Quantitative PCR for COX-2, 5-LOX, mPGES-1,
and 5-LOX–activating Protein mRNA Expression
Total RNA from pancreas samples was extracted using the TRIzol
RNA Kit (Invitrogen) as per the manufacturer’s instructions. Equal
quantities of DNA-free RNA were used in reverse transcription (RT)
reactions for making cDNA using SuperScript Reverse Transcriptase
(Invitrogen). Quantitative PCR was performed for COX-2, 5-LOX,
microsomal prostaglandin E synthase-1 (mPGES-1), and 5-LOX–
activating protein (FLAP). The quantitative real-time PCR reaction mix-
tures (primers and cDNA), 2× RT2 SYBR master mix (SABiosciences,
Frederick, MD), and nuclease-free water were incubated for 40 cycles
on a Bio-Rad IQ-5 real-time PCR System (Bio-Rad). Oligonucleotide
primer sequences used for COX-2 were given as follows: 5′-AGAAAC-
GGCTACCACATCCAA-3′ (sense) and 5′-GGGTCGGGAGTGGG-
TAATTT-3′ (antisense). Oligonucleotide primer sequences used for
5-LOX were given as follows: 5′-GGACCTCAGCATGTGG-
TATG-3′ (sense) and 5′-GCTGGGTCAGGGGTACTTTA-3′
(antisense). Oligonucleotide primer sequences used for mPGES-1 were
given as follows: 5′-GGAACGACATGGAGACCATCTAC-3′ (sense)
and 5′-TCCAGGCGACAAAAGGGTTA-3′ (antisense). Oligonucleotide
primer sequences used for FLAP were given as follows: 5′-GCCGGAC-
TGATGTACCTGTT-3′ (sense) and 5′-GGTGAGCGTCCTTCT-
CTGTC-3′ (antisense). Oligonucleotide primer sequences used for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were given as
follows: 5′-CCTCGTCCCGTAGACAAAATG-3′ (sense) and 5′-
TGAAGGGGTCGTTGATGGC-3′ (antisense). The cDNA samples
were amplified at 95°C for 3 minutes, 95°C for 30 seconds (5-LOX,
mPGES-1, FLAP) and 1 minute (COX-2), 60°C for 25 seconds (5-
LOX, mPGES-1, FLAP), and 55°C for 35 seconds (COX-2) for a total
of 40 cycles. The comparative C t method was used to compute relative
levels of target mRNAs by subtracting the C t values of the endogenous
control (GAPDH). Given that the relative value of the calibrator is 1.0,
the other samples were n-fold relative to the calibrator.
RT-PCR for p21, Cyclin D1, and Bcl-2 mRNA Expression
Total RNA from pancreas samples was extracted using the TRIzol
RNA Kit (Invitrogen) as per the manufacturer’s instructions. Equal
quantities of DNA-free RNA were used in RT reactions for making
cDNA using SuperScript Reverse Transcriptase (Invitrogen). RT-PCR
reactions were performed for p21, cyclin D1, and Bcl-2 using the Taq
polymerase, 10 mM deoxyribonucleotide triphosphates (dNTP), respec-
tive primers [3,28], and buffers from Invitrogen. For cyclin D1, dena-
turation at 94°C for 3 minutes was followed by 35 cycles at 94°C for
30 seconds, 60°C for 20 seconds, and 72°C for 45 seconds. Oligo-
nucleotide primer sequences used for the cyclin D1 gene were given as
follows: 5′-ATGGAACACCAGCTCCTGTG-3′ (sense) and 5′-ACC-
TCCAGCATCCAGGTGGC-3′ (antisense). For p21, denaturation at
94°C for 3 minutes was followed by 35 cycles at 94°C for 30 seconds,
60°C for 20 seconds, and 72°C for 45 seconds. Oligonucleotide primer
sequences used for p21 were given as follows: 5′-TCCTGGTGATG-
TCCGACCTG-3′ (sense) and 5′-TCCGTTTTCGGCCCTGAG-3′
(antisense). For Bcl-2, denaturation at 94°C for 2 minutes was followed
by 35 cycles at 94°C for 30 seconds, 58°C for 30 seconds, and 72°C
for 45 seconds. Oligonucleotide primer sequences used for Bcl-2 were
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given as follows: 5′-CCAAGAATGCAAAGCACATCC-3′ (sense) and
5′-CCCAGCCTCCGTTATCCTG-3′ (antisense). The PCR products
were visualized and photographed under UV illumination and analyzed
by densitometry.
Statistical Analysis
The data are presented as means ± SE. Differences in body weights
were analyzed by analysis of variance. Statistical differences between
control and treated groups were evaluated using Fisher’s exact test for
PDAC incidence, and unpaired t test with Welch’s correction was
used for PanIN and PDAC lesions. Differences between groups are
considered significant at P < .05.
Results
General Observations
The p48Cre/+–LSL-KrasG12D/+ and the Fat-1–p48Cre/+–LSL-KrasG12D/+
mice fed the 10% safflower oil experimental diets had similar body
weight gains at the end of the experiment. However, WT and Fat-1
mice had slightly higher body weight gains (P < .05) in comparison
with the p48Cre/+–LSL-KrasG12D/+ and the Fat-1–p48Cre/+–LSL-
KrasG12D/+ mice (Figure 1C ). None of the animals fed the experimental
diets exhibited any observable toxicity or any gross changes attributable
to liver, kidney, or lung toxicity despite notable difference in the pan-
creatic weights as described below.
Expression of Fat-1 Gene Delays the Progression of
PanIN Lesions to PDAC
To test whether increasing the pancreatic tissue levels of n-3 FAs
in Fat-1 transgenic mice may be associated with a lower risk for tumori-
genesis than in p48Cre/+–LSL-KrasG12D/+mice, we evaluated tumori-
genesis and analyzed PUFA in the pancreas. C57BL/6 WT and Fat-1
mice fed AIN-76A diet containing 10% safflower oil showed no evi-
dence of PanIN lesions or carcinoma (Figure 2, A and B); however,
Kras-activated mice showed 100% penetrance with PanIN lesions
and carcinoma (Figure 2, C and D). Significant difference in the size
and texture of the pancreata was noticed among C57BL/6 WT,
Fat-1, p48Cre/+–LSL-KrasG12D/+, and Fat-1–p48Cre/+–LSL-KrasG12D/+
mice (Figure 2, E and F ). Pancreas from C57BL/6 WT and Fat-1
mice fed AIN-76A diet containing 10% safflower oil weighed about
0.17 to 0.3 g (Figure 2G ). However, the pancreas from p48Cre/+–
LSL-KrasG12D/+ mice weighed 0.6 g, almost two-fold more than the
pancreas from WT mice. A significant decrease in pancreas weights
(∼22%; P < .02) was observed in Fat-1–p48Cre/+–LSL-KrasG12D/+ mice
(Figure 2, F and G ). To assess effect of Fat-1 gene on K-ras–activated
pancreatic tumorigenesis, we measured the PDAC incidence and the
extent of pancreas invaded by carcinoma. As shown in Figure 2,
H and I , there is a marked difference in the incidence of PDAC
formation and degree of invasion between p48Cre/+–LSL-KrasG12D/+
and Fat-1–p48Cre/+–LSL-KrasG12D/+ mice. Fat-1–p48Cre/+–LSL-
KrasG12D/+ and p48Cre/+–LSL-KrasG12D/+ mice spontaneously develop
pancreatic cancer arising from progression of PanINs through low-
grade PanINs (1A and 1B) to high-grade PanINs (PanIN-2 and
PanIN-3) (Figure 2, C andD). Figure 2H summarizes the effectiveness
of endogenous n-3 PUFAs on PDAC incidence by comparison of
Fat-1–p48Cre/+–LSL-KrasG12D/+ and p48Cre/+–LSL-KrasG12D/+ mice.
Over an observation period of 41 weeks of age, the p48Cre/+–LSL-
KrasG12D/+ mice had an incidence of 50% (percentage of mice with
PDAC), whereas Fat-1–p48Cre/+–LSL-KrasG12D/+ mice showed an
incidence of 8%PDAC (P < .02), as determined with histologic analysis
(P < .02). The p48Cre/+–LSL-KrasG12D/+ mice showed about 22% of
the pancreas involved with invasive ductal carcinoma, whereas Fat-1–
p48Cre/+–LSL-KrasG12D/+ mice showed only about 1% of the pancreas
involvedwith invasive ductal carcinoma (Figure 2I ). In addition, p48Cre/+–
LSL-KrasG12D/+ mice developed, on the average, about 182 PanIN-1, 215
PanIN-2, and 192 PanIN-3 lesions, whereas Fat-1–p48Cre/+–LSL-
KrasG12D/+ mice had a significant increase in PanIN-1 lesions (288) and
significant inhibition of PanIN-3 (98) lesions (Figure 2J ).
FA Profiles of Pancreatic Tissues of Fat-1–p48Cre/+–
LSL-KrasG12D/+, p48Cre/+–LSL-KrasG12D/+, Fat-1,
and C57BL/6 Mice
Analysis of the total lipids extracted from the pancreata showed dis-
tinct lipid profiles among Fat-1–p48Cre/+–LSL-KrasG12D/+, p48Cre/+–
LSL-KrasG12D/+, Fat-1, andWTmice (Table 1). There are significantly
higher levels of n-6 FAs [20:4n-6 (AA) and 22:5n-6] and much lower
concentrations of n-3 FAs {18:3n-3, 20:5n-3 [EPA], 22:5n-3 [docosa-
pentaenoic acid (DPA)], and 22:6n-3 [DHA]} in the pancreas derived
from WT and p48Cre/+–LSL-KrasG12D/+ mice than in the pancreata
from Fat-1–p48Cre/+–LSL-KrasG12D/+ and Fat-1 mice. The ratios of
the C ≥ 20 n-6 FA, AA (20:4n-6), to the n-3 FAs (EPA, DPA,
and DHA) were 43.8, 0.23, 27, and 1.02 in WT, Fat-1, p48Cre/+–
LSL-KrasG12D/+, and Fat-1–p48Cre/+–LSL-KrasG12D/+ transgenic mice,
respectively (Table 1). Notably, we observed that p48Cre/+–LSL-
KrasG12D/+–induced pancreatic tumors showed significant blockage
of chain elongation steps > C:20 FAs (Table 1). In addition, p48Cre/+–
LSL-KrasG12D/+ mouse pancreas showed significantly higher levels of
AA (C20:4) compared with Fat-1–p48Cre/+–LSL-KrasG12D/+ mouse
pancreas (Figure W1).
Table 1. Profiles of Polyunsaturated n-6 and n-3 FAs in Pancreas from WT, Fat-1, Kras, and
Fat-1–Kras Transgenic Mice.
PUFAs WT Kras Fat-1 Fat-1–Kras
14:0 1.04 ± 0.16 1.71 ± 0.15 1.31 ± 0.18 1.92 ± 0.22
16:0 23.21 ± 0.10 22.50 ± 2.58 19.63 ± 1.44 21.35 ± 1.95
16:1 5.11 ± 1.29 8.54 ± 0.42 7.48 ± 1.62 9.05 ± 1.96
18:0 8.36 ± 0.74 3.40 ± 1.05 3.20 ± 0.51 2.87 ± 0.38
18:1 22.73 ± 2.72 24.05 ± 2.96 30.35 ± 1.68 25.88 ± 3.70
18:2n-6 26.19 ± 3.17 32.70 ± 2.98 32.62 ± 3.79 34.97 ± 4.01
18:3n-6 0.11 ± 0.02 0.14 ± 0.04 0.09 ± 0.02 0.12 ± 0.02
18:3n-3 0.02 ± 0.00 0.03 ± 0.02 1.95 ± 0.82 0.33 ± 0.21
20:5n-3 0.01 ± 0.01 0.00 ± 0.00 1.33 ± 0.55*** 0.45 ± 0.38***
20:3n-6 0.27 ± 0.03 0.30 ± 0.06 0.13 ± 0.04 0.19 ± 0.04
20:4n-6 10.52 ± 1.47 4.35 ± 1.69 0.46 ± 0.15** 1.21 ± 0.60**
22:4n-6 0.55 ± 0.07 0.76 ± 0.32 0.13 ± 0.04 0.25 ± 0.09
22:5n-6 0.71 ± 0.12 0.60 ± 0.24 0.05 ± 0.02 0.12 ± 0.03
22:5n-3 0.03 ± 0.00 0.02 ± 0.01 0.21 ± 0.07* 0.28 ± 0.17*
22:6n-3 0.20 ± 0.03 0.14 ± 0.07 0.41 ± 0.18 0.45 ± 0.21*
n-3 ≥ C20 0.23 ± 0.04 0.16 ± 0.07 2.01 ± 0.77* 1.21 ± 0.80*
n-6 ≥ C20 12.16 ± 1.62 6.08 ± 2.28 0.85 ± 0.23** 1.82 ± 0.75**
n-6/n-3 113.98 219.64 9.95*** 34.75***
AA/EPA + DPA + DHA 43.8 27 0.23* 1.02*
Total lipids of the pancreas were extracted and FAMEs were subjected to analysis by gas chroma-
tography. The values (molar percent of total FAs) are means of six separate measurements ± SD (N =
3–6). The significant differences of important FAs between p48Cre/+–LSL-KrasG12D/+ and Fat-1 or
Fat-1–p48Cre/+–LSL-KrasG12D/+mice were analyzed by unpaired t test withWelch’s correction. Values
are means ± SE (N = 3–6). *P ≤ 0.05 to 0.01, **P ≤ 0.01 to 0.001, and ***P < 0.001 to 0.0001.
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Inhibition of Proliferation and Induction of Apoptosis by
Endogenous n-3 PUFAs in PanINs and Carcinoma
of the Pancreas
Figure 3 (A–C ) summarizes the effects of n-3 PUFAs on tumor cell
proliferation as measured by fraction of PCNA-positive cells (labeling
index). PCNA labeling indices were significantly lowered in the pan-
creas of Fat-1–p48Cre/+–LSL-KrasG12D/+ animals (Figure 3, B and C )
compared with pancreas from p48Cre/+–LSL-KrasG12D/+.Quantification
of the PCNA staining showed 85 ± 3.6 (mean ± SEM) PCNA label-
ing index in p48Cre/+–LSL-KrasG12D/+ PDAC compared with 20 ±
1.4 PCNA labeling index in Fat-1–p48Cre/+–LSL-KrasG12D/+ PDAC,
accounting for a decrease in the proliferation index by ∼75% (P <
.0001) (Figure 3C ). Figure 3, D to F , summarizes the effects of
n-3 PUFAs on tumor cell apoptosis. Qualitative microscopic exam-
ination of TUNEL-stained sections showed a substantial increase in
TUNEL-positive cells in the pancreatic tissue of Fat-1–p48Cre/+–
LSL-KrasG12D/+ mice compared with that of p48Cre/+–LSL-KrasG12D/+
mice. The quantification of apoptotic staining showed 12.8 ± 1.7
(mean ± SEM) TUNEL-positive cells (apoptotic index) in PDAC from
p48Cre/+–LSL-KrasG12D/+ mice compared with 18.20 ± 3.4 (mean ± SEM)
TUNEL-positive cells in PDAC from Fat-1–p48Cre/+–LSL-KrasG12D/+
mice, accounting for an increase in the apoptotic index of >29% (P <
.0001) (Figure 3F ). Figure 3, G and H , summarizes the effects of n-3
PUFAs on p21 expression in PanIN lesions and in ductal cells. A sig-
nificant increase in the expression of p21 was seen in the pancreatic
tissues of Fat-1–p48Cre/+–LSL-KrasG12D/+ mice (Figure 3, G and H ).
Differential Expression and/or Modulation of COX-2, 5-LOX,
β-catenin, Bcl-2, Caspase-3, PCNA, p21, Cyclin D1, Bcl-2,
mPGES-1, and FLAP in the Pancreata of Transgenic Mice
Because COX-2 and 5-LOX play critical roles in AAmetabolism and
Wnt/β-catenin pathways are active in pancreatic tumor development
[2,3,5,6], we examined the expression of these pathways in Fat-1–
expressing mice. To determine whether Fat-1 expression decreases
Figure 3. Effect of Fat-1 expression on cell proliferation (A–C), apoptosis (D–F), and p21 (G and H) in pancreatic tumors. Immunohisto-
chemical analysis was performed with paraffin-embedded and microsectioned pancreatic tissues as described in Materials and Methods
section. A, D, and G represent pancreas from p48Cre/+–LSL-KrasG12D/+ mice, and B, E, and H represent pancreas from Fat-1–p48Cre/+–
LSL-KrasG12D/+ mice. (A and B) Immunohistochemical analysis of PCNA expression in PanIN lesions and in ductal cells. (C) Significant
differences in proliferative indices were observed between the groups. (D–F) Effect of Fat-1 expression on apoptosis in pancreatic tissues
by TUNEL assay. A significant increase in TUNEL-positive cells was observed in pancreatic lesions and PDAC because of Fat-1 expression
in mice. (F) Significant differences were observed in apoptotic indices between PanIN and PDAC of Fat-1–p48Cre/+–LSL-KrasG12D/+
and p48Cre/+–LSL-KrasG12D/+ mice. (G and H) Immunohistochemical analysis of p21 expression in PanIN lesions and in ductal cells. A
significant increase in expression of p21 was seen in the pancreatic tissues of Fat-1–p48Cre/+–LSL-KrasG12D/+ mice.
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COX-2 and 5-LOX, thereby modulating several related signaling
molecules and exerting a role in anticancer effects, we analyzed protein
and mRNA expression profiles by IHC,Western immunoblot analysis,
and RT and/or real-time PCR (Figures 4, 5, and W2). Pancreatic tis-
sues from Fat-1–p48Cre/+–LSL-KrasG12D/+ mice exhibited significantly
reduced protein expressions of COX-2, 5-LOX, PCNA, Bcl-2, and
β-catenin compared with pancreatic tissues from p48Cre/+–LSL-
KrasG12D/+ mice (Figures 4, A–D, 5, A and B, and W2). In addition,
caspase-3 and p21 expressions were slightly higher in the pancreata
of Fat-1–p48Cre/+–LSL-KrasG12D/+ mice compared with p48Cre/+–
LSL-KrasG12D/+ mice (Figures 3, G and H , and 5A ).
The real-time PCR results showed a significant decrease in COX-2,
mPGES-1, 5-LOX, and FLAP mRNA expressions in the pancreatic
tumor tissues of Fat-1–p48Cre/+–LSL-KrasG12D/+ (Figure 4E ), further
confirming the results observed by IHC and Western immunoblot
analysis. RT-PCR analysis also demonstrated that pancreatic tissues
from Fat-1–p48Cre/+–LSL-KrasG12D/+ mice exhibited significant
decreases in cyclin D1 and Bcl-2 with an increase in p21 expressions
(Figure 5, C and D). These results support the immunohistologic
and/or Western immunoblot analysis observations.
Discussion
There is increasing evidence that dietary intake of n-3 FAs suppresses
progression of breast, prostate, and colon cancers, and a number of
epidemiological and preclinical studies implicate mostly a protective
role of n-3 PUFAs against pancreatic cancer [18–20,35–43]. How-
ever, variable diets were a confounder in the earlier studies, and there
is limited understanding of how dietary FAs may affect the process of
pancreatic carcinogenesis particularly Kras-activated tumor progres-
sion. In an attempt to eliminate dietary variables, we compared the
incidence and characteristics of pancreatic tumors in WT and K-ras
transgenic mice with and without co-expression of Fat-1, which increases
the percentage of endogenous n-3 PUFAs. All animals were main-
tained on identical diets. Previously, decreased tumor growth rates in
N -nitrosobis(2-oxopropyl)amine–induced pancreatic cancer were
observed in hamsters fed a high n-3 fat diet [27]. To date, several of
the in vivo studies regarding the effect of different PUFA-rich diets during
pancreatic carcinogenesis have used carcinogen-induced cancers with
limited ductal tumor cell origin and not much associated with K-ras
mutations [26,27,44]. The, relevance of these chemically induced pan-
creatic models to human pancreatic cancer, which is predominately
ductal cell origin and >95% associated with K-ras mutations, is less. In
that context, transgenic models are highly relevant to human pancreatic
cancer. Recently, Strouch et al. have shown that a high n-3 fat diet
mitigates pancreatic precancer by inhibition of cellular proliferation
through induction of cell cycle arrest and apoptosis in the EL-Kras mice
and human pancreatic cancer cell lines [35]. To our knowledge, this is
the first study to evaluate the effects of endogenous n-3 PUFA derived
from n-6 PUFA on transgenic mice that develop a distinct PanIN to
PDAC paradigm. The most striking finding is that there is a dramatic
inhibition of PDAC incidence and a decreased frequency of PanIN-3
formation and their progression to PDAC in Fat-1–p48Cre/+–LSL-
KrasG12D/+ transgenic mice. These results clearly support the notion that
Figure 4. Immunohistochemical analysis of the effect of Fat-1 expression on AA metabolism in pancreatic tumors. Immunohistochem-
ical analysis was performed with paraffin-embedded and microsectioned pancreatic tissues as described in Materials and Methods
section. Immunohistochemical analysis of COX-2 (A and B) and 5-LOX (C and D) expressions in PanIN lesions/PDAC. A and C represent
pancreas from p48Cre/+–LSL-KrasG12D/+ mice, and B and D represents pancreas from Fat-1–p48Cre/+–LSL-KrasG12D/+ mice. A significant
decrease in the expression of COX-2 and 5-LOX was seen in the pancreatic tissues of Fat-1–p48Cre/+–LSL-KrasG12D/+ mice. (E) Effect of
Fat-1 expression on the mRNA expression levels of COX-2, mPGES-1, 5-LOX, and FLAP as determined by real-time PCR (Kras represents
p48Cre/+–LSL-KrasG12D/+ and Fat-1–Kras represents Fat-1–p48Cre/+–LSL-KrasG12D/+). A significant decrease in the expression of COX-2,
mPGES-1, 5-LOX, and FLAP was seen in the pancreatic tissues of Fat-1–p48Cre/+–LSL-KrasG12D/+ mice.
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increased tissue levels of n-3 FAs can reduce pancreatic tumor progression
(Figure 2). Furthermore, our data show that the cellular proliferation rate
in PanIN lesions and PDAC was significantly decreased in the Fat-1–
p48Cre/+–LSL-KrasG12D/+ transgenic mice (Figures 3 and 5).
The COX-2/5-LOX and Wnt/β-catenin signaling pathways are
active in pancreatic cancers [2,3,5,6]. There is constitutively high
expression and activation of COX-2 and β-catenin in human PanIN
lesions and PDAC. COX-2 activation enhances the production of PGs
from AA that subsequently promote pancreatic inflammation and neo-
plasia. Therefore, we postulate that strategies aimed at simultaneous
disruption of the COX-2/5-LOX and Wnt/β-catenin signaling path-
ways may produce effective chemopreventive and antitumorigenic
effects. Our work shows that Fat-1 expression affects cell growth and
the production of eicosanoids that are likely to contribute to cancer cell
growth by effectively decreasing COX-2/5-LOX and β-catenin signal-
ing pathways. This study supports the possibility that inhibition of
these signaling pathways by n-3 PUFAs contributes to the significant
decrease in tumor development with Fat-1 expression.
The endogenous n-3 PUFAs are likely to play a role both in retard-
ing the transformation process, which leads to the initial formation of
pancreatic precursors because of K-ras mutation, and then in damp-
ening the proliferative ability of the precancerous lesions once they
develop. Previous findings in prostate, mammary, skin, and colon pre-
cancerous conditions demonstrated that administration of n-3 PUFA-
rich diets suppressed tumor progression [40–43]. Our results extend
this idea to pancreatic cancer development in a preclinical setting that
recapitulates human disease and support previously identified in vitro
and in vivo effects of n-3 PUFAs during pancreatic carcinogenesis. One
of the notable changes accompanying the reduction of PDAC forma-
tion is a significantly lower n-6/n-3 ratio, a decrease in tumor cell pro-
liferation, and an increase in apoptosis associated with alteration in
various signaling molecules as evidenced by RT-PCR, IHC, and/or
Western blot analysis.
This genetic approach of modifying FA composition by converting
n-6 to n-3 FAs endogenously not only effectively increases the absolute
amount of n-3 FAs but also significantly decreases the level of n-6 FAs
(Table 1 and Figure W1), leading to a balanced ratio of n-6 to n-3 FAs
in the pancreas. The increase in apoptosis (Figure 3) is noteworthy
because apoptosis is progressively inhibited during PanIN progression
to PDAC development. Therefore, it is possible that the observed pro-
tective effect of n-3 PUFA is due, in part, to the enhanced deletion of
cells through the activation of targeted apoptosis [45].
More than 80% of PDAC patients show insulin resistance and
type 2 diabetes, and epidemiological studies in humans showed that
populations traditionally consuming high levels of long-chain n-3
PUFAs display a lower prevalence of type 2 diabetes [46]. Interest-
ingly, data from a clinical study suggest that the positive influence of
long-chain n-3 PUFA supplementation on insulin sensitivity is greater
in obese populations that display an inflammatory phenotype [47].
These data lend support to our findings, which indicate that the
anti-inflammatory actions of n-3 PUFAs in metabolic tissues are a
key to the positive impact of long-chain n-3 PUFAs on insulin
sensitivity. A clinical study showed that patients with pancreatic cancer
given approximately 2 g of EPA and 1 g of DHA per day for 7 weeks
Figure 5. (A and B) Western blot analysis (A) and densitometry (B) quantification of the effect of Fat-1 expression on expression of COX-2,
5-LOX, β-catenin, caspase-3, and PCNA in PDAC (R represents p48Cre/+–LSL-KrasG12D/+, FR represents Fat-1–p48Cre/+–LSL-KrasG12D/+,
and *P= .05, **P< .05–0.01, ***P< .001–0.0001, respectively). (C and D) RT-PCR (C) and densitometry (D) quantification of the effect of
Fat-1 expression on the mRNA expression levels of p21, cyclin D1, and Bcl-2 in the pancreatic tumor tissue (R represents p48Cre/+–LSL-
KrasG12D/+, FR represents Fat-1–p48Cre/+–LSL-KrasG12D/+, and *P < .05, **P < .05–0.01, ***P < .001–0.0001, respectively).
Neoplasia Vol. 14, No. 12, 2012 Endogenous n-3 PUFAs Delay PDAC Progression Mohammed et al. 1257
showed significant weight gain and improvement in functional status
and appetite [48]. The results presented here show that an increased
n-3 PUFA level in the pancreas is associated with diminished inflam-
matory changes in the organ. Particularly noteworthy in this context is
the reduction of COX-2 and 5-LOX, because these contribute to mor-
bidity and prognosis of the disease. However, detailed studies on insulin
signaling and glucose metabolism are warranted.
Dietary n-3 PUFAs are well known for both their anti-inflammatory
and tumor-suppressing properties. Important n-3 PUFAs involved in
human nutrition are α-linolenic acid, EPA, and DHA [36]. Further-
more, the synthesis of longer chain n-3 FAs from linolenic acid is
competitively slowed by n-6 analogs. Therefore, the concentration of
long-chain n-3 PUFAs in tissues is enhanced when they are directly
ingested or when the competing amounts of n-6 FAs are relatively
small. The lipid data in Fat-1–p48Cre/+–LSL-KrasG12D/+ mice (Table 1
and Figure W1) demonstrate significantly decreased levels of n-6
PUFAs, particularly AA in the pancreas. Activation of Kras signaling
leads to blockage of long-chain FA synthesis and, notably, accumu-
lation of C20:4 AA, the most important substrate for COX-2– and
5-LOX–mediated protumorigenic metabolites. In contrast, in the pres-
ence of Fat-1 gene, there are significantly lower levels of AA and higher
n-3 PUFA present in pancreatic tissues, even with activated Kras signal-
ing. In addition, EPA is a precursor of resolvin E1 and resolvin E2, the
potent anti-inflammatory substances described and characterized
recently [49]. Future studies are needed to address the role of resolvins
in pancreatic cancer.
Several other signaling pathways also affected by Fat-1 expression
may contribute to prevention of tumor development and progression.
EPA and DHA also induce cancer cell apoptosis and decrease of Bcl-2
expression [41], and Fat-1 gene expression in tumor cells reduces pro-
tein expression of β-catenin and cyclin D1 as well [41]. Our work
(Figures 4, 5, and W2), as well as other studies [50], show that n-3
PUFAs block tumor cell growth at least in part through inhibition of
Wnt/β-catenin and COX-2 signaling pathways [50]. The higher n-3
PUFA in the pancreatic tissues of Fat-1 gene expressing Kras mice
therefore significantly inhibited the progression of PanIN lesions to
carcinoma in part through cell cycle arrest and targeted apoptosis in
the mutant Kras cells. The potential reasons for this could be the
modulatory effects of n-3 PUFA on the accumulated AA because of
Kras mutation by inhibiting COX-2 and 5-LOX pathways, thereby
reducing tumor cell proliferation and increasing apoptosis.
In summary, this is the first exploration of the function of the Fat-1
gene in pancreatic tumor cells in vivo. We have shown that Fat-1 gene
expression inhibits tumor cell proliferation, induces tumor cell apop-
tosis, and alters AA metabolism. Our results suggest that endogenous
n-3 PUFAs delay the progression of PanIN-1 and PanIN-2 to PanIN-3
and PDAC. Elevating n-3 PUFAs may be an important strategy to
delay/prevent pancreatic cancer in high-risk patients.
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Figure W2. Immunohistochemical analysis of the effect of Fat-1 expression on expression of Bcl-2 and β-catenin in pancreatic tumors.
Immunohistochemical analysis was performed with paraffin-embedded and microsectioned pancreatic tissues as described in Materials
andMethods section. Immunohistochemical analysis of Bcl-2 (A and B) and β-catenin (C and D) expressions in PanIN lesions/PDAC. A and
C represent pancreas from p48Cre/+–LSL-KrasG12D/+ mice, and B, D, and F represent pancreas from Fat-1–p48Cre/+–LSL-KrasG12D/+ mice.
A significant decrease in the expression of Bcl-2 and β-catenin was seen in the pancreatic tissues of Fat-1–p48Cre/+–LSL-KrasG12D/+ mice.
Figure W1. Effect of Fat-1 expression on AA. A significant decrease
in the AA synthesis was observed in the pancreatic tissues of
Fat-1–p48Cre/+–LSL-KrasG12D/+ mice.
